05 Nov, 2025
Cancer remains one of the most serious health challenges in
India. Every year, more than 1.3 million people are newly diagnosed and nearly 850,000 lives are lost to the disease.
Most of the cancers are frequently overlooked in their early stages, with many cases progressing to advanced disease
before diagnosis. Breast cancer, lung cancer, colorectal cancer, and ovarian cancer together contribute to nearly 50%
of cancer-related deaths.
Cancer remains one of the most serious health challenges in
India. Every year, more than 1.3 million people are newly diagnosed and nearly 850,000 lives are lost to the disease.
Most of the cancers are frequently overlooked in their early stages, with many cases progressing to advanced disease
before diagnosis. Breast cancer, lung cancer, colorectal cancer, and ovarian cancer together contribute to nearly 50%
of cancer-related deaths.
Cancer remains one of the most serious health challenges in
India. Every year, more than 1.3 million people are newly diagnosed and nearly 850,000 lives are lost to the disease.
Most of the cancers are frequently overlooked in their early stages, with many cases progressing to advanced disease
before diagnosis. Breast cancer, lung cancer, colorectal cancer, and ovarian cancer together contribute to nearly 50%
of cancer-related deaths.
Cancer remains one of the most serious health challenges in India. Every year, more than 1.3 million
people are newly diagnosed and nearly 850,000 lives are lost to the disease. Most of the cancers are frequently
overlooked in their early stages, with many cases progressing to advanced disease before diagnosis.
Lung cancer remains one of the deadliest cancers due to late
detection. BridgeInDx is building AI-powered tests that combine biomarker panels with patient risk factors, enabling
earlier detection and triage.
Ovarian cancer is often called the “silent killer”
because symptoms are vague and most women are diagnosed at advanced stages.
Colorectal cancer is one of the fastest-growing
cancers in India, often undiagnosed until late stages.
We are developing urine-based rapid tests capable of
detecting infections, hematuria, and bladder cancer risk factors.
Dogs and cats are family
members, and their health requires attention. BridgeInDx is developing AI-based LFAs for common cancers in canines and
felines.
We believe in the power of
collaboration. BridgeInDx actively partners with academic institutions, incubators, and healthcare innovators to
develop high-potential diagnostic ideas.
Pioneering
non-invasive methods for comfortable and accessible diagnostics.
Seeking to establish their footprint in India fast-growing diagnostics market.
Read More
Our R&D pipeline follows a robust, stepwise approach to ensure both scientific credibility and practical usability.
• Concept and Biomarker Selection: Identifying and validating the most reliable biomarkers.
We believe diagnostics must not only be effective but also visible and trusted.
Read More
Indias diagnostics market is expanding at an unprecedented pace, projected to grow from 10 billion in 2022 to nearly 1,500 billion by 2028.
Read More
Lung cancer accounts for 5.9% of all cancersand 8.1% of cancer-related deaths in India, with smoking linked to nearly 80% of cases.
Read More
Ovarian cancer is the third most common gynecologic cancer in India, with nearly 60,000 new cases reported annually and high mortality due to late detection.
Read More
Colorectal cancer is one of the fastest-growing cancers in India, particularly in urban and semi-urban regions.
Read More
Bladder health issues, including urinary tract infections (UTIs)and bladder cancer, remain largely underdiagnosed in India.
Read More
With over 30 million pet dogs and 3 million pet cats in India and a pet care industry growing at 12 to 15% CAGR, companion animal diagnostics is an emerging...
Read More
Conducting rigorous sensitivity and specificity testing in both human and veterinary samples.
Read More
Partnering with hospitals, primary health centers, and veterinary clinics for real-world validation.
Read More
Preparing for pilot-scale manufacturing, packaging, distribution, and post-market monitoring. By combining artificial intelligence with biomarker science, BridgeInDx creates diagnostic solutions that are accurate, scalable, and accessible for all.
Read More
Showcasing new diagnostic innovations to the medical and veterinary communities.
Read More
Building credibility through partnerships and research publications.
Read More
Promoting accessibility, affordability, and scientific innovation through engaging online content.
Read More
Bringing awareness programs and diagnostic camps to rural populations and pet owners in regional languages. BridgeInDx is building a reputation as a brand that represents trust, accessibility, and innovation.
Read More
At BridgeInDx, we are addressing this critical unmet need. AI-integrated rapid tests that allow for quick detection and ongoing monitoring of cancers, helping patients receive care at the right time.
Call Us Anytime:
+91-7893012370Email Us:
info@bridgeindx.com
Ensuring diagnostic solutions are available in urban and rural areas.
